Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
198.59
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
July 26, 2021
Health Canada has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at...
Via
Benzinga
Yellow Card
July 12, 2021
The price of oil fell about 1% today.
Via
Talk Markets
BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients
July 09, 2021
The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The...
Via
Benzinga
PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer
July 07, 2021
PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership...
Via
Benzinga
Fireworks Display
July 05, 2021
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.
Via
Talk Markets
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
July 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
July 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market
July 03, 2021
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Is This Chinese Biopharma Stock Still a Buy?
June 28, 2021
The pharmaceutical company had a solid first quarter and boasts a nice pipeline.
Via
The Motley Fool
Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development
June 26, 2021
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
June 21, 2021
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Chicago Fed National...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
5 Stocks To Watch For June 21, 2021
June 21, 2021
Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime shopping event beginning...
Via
Benzinga
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
June 19, 2021
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong...
Via
Talk Markets
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
June 12, 2021
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
June 11, 2021
BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (...
Via
Benzinga
BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer
June 09, 2021
Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a...
Via
Benzinga
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
June 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc...
Via
Benzinga
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
May 22, 2021
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200...
Via
Talk Markets
BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer
May 21, 2021
BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a...
Via
Benzinga
BeiGene's Brukinsa US Application For Expanded Use Under FDA Review
May 19, 2021
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL)...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
June 07, 2021
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...
Via
Benzinga
Exposures
Product Safety
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
May 08, 2021
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine...
Via
Talk Markets
Exposures
COVID-19
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
May 03, 2021
Two of AbbVie's most important assets could get a lot harder to sell.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
A Heavy News Day And Crypto
April 28, 2021
Israeli TEVA reported Q1 sales which missed forecasts at $4 bn, leading to a 2.6% drop in its price earlier today.
Via
Talk Markets
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
April 28, 2021
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against...
Via
Benzinga
Exceptions To A Low Period
April 25, 2021
This past week served as a negative period for my stock holdings, with a couple of exceptions. Here I discuss what those exceptions were and how they moved.
Via
Talk Markets
Currency Manipulation
April 16, 2021
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53.
Via
Talk Markets
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
April 10, 2021
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in...
Via
Talk Markets
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.